4.7 (112) · $ 20.99 · In stock
See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.
Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP
The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Madrid, Spain—February 19–22, 2020
A1C Data, BYDUREON BCise® (exenatide extended-release) injectable suspension 2 mg
Research_Review_Special_Report_2023_Update_of_NZSSD_Type_2_Guidelines by WBOP PHO - Issuu
A1C and Weight Results RYBELSUS® (semaglutide) tablets 7 mg or 14 mg
A1CNow Systems Overview - PTS Diagnostics
1-year weight change after diabetes diagnosis and long-term incidence and sustainability of remission of type 2 diabetes in real-world settings in Hong Kong: An observational cohort study
Frontiers Changes in body weight and cardiovascular risk factors in a Chinese population with type 2 diabetes mellitus: a longitudinal study
Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review
Frontiers Changes in body weight and cardiovascular risk factors in a Chinese population with type 2 diabetes mellitus: a longitudinal study
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study
Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP
Cardiovascular Outcomes Trial (CVOT) RYBELSUS® (semaglutide) tablets 7 mg or 14 mg
Weight loss and benefits for cardiovascular disease (CVD)